Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0268318 (
ICP
)
10,007
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To identify the effect of
hOGG1
methylation, Ser326Cys polymorphism and their interactions on the risk of coal-borne arsenicosis, 113 coal-borne arsenicosis subjects and 55 reference subjects were recruited. Urinary arsenic contents were analyzed with
ICP
-MS.
hOGG1
methylation and Ser326Cys polymorphism was measured by mehtylation-specific PCR and restriction fragment length polymorphism PCR in PBLCs, respectively. The results showed that the prevalence of methylated
hOGG1
and variation genotype (326
Ser/Cys
& 326
Cys/Cys
) were increased with raised levels of urinary arsenic in arsenicosis subjects. Increased prevalence of methylated
hOGG1
and variation genotype were associated with raised risk of arsenicosis. Moreover, the results revealed that variant genotype might increase the susceptibility to
hOGG1
methylation. The interactions of methylated
hOGG1
and variation genotype were also found to contribute to increased risk of arsenicosis. Taken together,
hOGG1
hypermethylation,
hOGG1
variants and their interactions might be potential biomarkers for evaluating risk of coal-borne arsenicosis.
...
PMID:hOGG1 promoter methylation, hOGG1 genetic variants and their interactions for risk of coal-borne arsenicosis: A case-control study. 3200 20